Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines
The announcement last night that Affymax (NASDAQ: AFFY) is recalling all lots of its red blood cell stimulating medicine Omontys could have broader implications for how the Food and Drug Administration (FDA) evaluates similar drugs going forward.